Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity

Blood

Volumn 110, Issue 13, 2007, Pages 4588-4598

  Zeiser, Robert ^a,b   Youssef, Sawsan ^a   Baker, Jeanette ^a   Kambham, Neeraja ^a   Steinman, Lawrence ^a   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GUANOSINE TRIPHOSPHATASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; MEVALONIC ACID; STAT6 PROTEIN; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; CYTOKINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; STAT6 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOWN REGULATION; ENZYME INHIBITION; GRAFT VERSUS LEUKEMIA EFFECT; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; POLARIZATION; PRENYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ANIMAL; ANTIGEN PRESENTATION; CHEMOPROPHYLAXIS; CYTOLOGY; DRUG EFFECT; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PREMEDICATION; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; CHEMOPREVENTION; CYTOKINES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; MICE; MICE, KNOCKOUT; PREMEDICATION; PYRROLES; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TH2 CELLS;

EID: 39649089195     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-106005     Document Type: Article

References (46)

1. Ferrara J, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003;78:181-187.
2. Shlomchik W, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
3. Ferrara J, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
4. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host-disease (GVHD) prevention. Immunol Rev. 1997;157:79-109.
5. Lin M, Storer B, Martin PJ, et al. Relation of an interleukin-10 promotor polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201-2210.
6. Leung BP, Sattar N, Crilly A, et al. A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.
7. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
8. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th-1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203:401-412.
9. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17:905-907.
10. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-2322.
11. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem. 1996;65:241-269.
12. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
13. Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004;172:85-93.
14. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607-1608.
15. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:2015-2021.
16. Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation. 2005;79:372-374.
17. + regulatory T cell function by calcineurin dependent interleukin-2 production. Blood. 2006;108:390-399.
18. Cao YA, Wagers AJ, Beilhack A, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A. 2004;101:221-226.
19. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficiency of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640-648.
20. + regulatory T cells preserve graft-vs-tumor activity while inhibiting graft-vs-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1149.
21. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T cell subsets. Blood. 2005;106:1113-1122.
22. Krutzik P, Clutter MR, Nolan GP. Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J Immunol. 2005;175:2357-2365.
23. Lerner K, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6:367-371.
24. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets, II: in vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986;163:998-1011.
25. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes. 2006;55:40-49.
26. Darnell JE Jr. STATs and gene regulation. Science. 1997;7:1630-1635.
27. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-319.
28. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. Science. 2005;308:523-529.
29. Usui T, Preiss JC, Kanno Y, et al. T-bet regulates Th-1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med. 2006;203:755-766.
30. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versushost disease and graft-versus-leukemia effect. Blood. 2001;97:2886-2895.
31. Campbell M, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66:8707-8716.
32. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
33. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289-1298.
34. + lymphoid engraftment. J Immunol. 1994;152:1004-1013.
35. Holler E, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:237-241.
36. Baker K, et al. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant. 1999;23:1123-1129.
37. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther. 2001;15:211-218.
38. Cilla D, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687-695.
39. Dostal L, Whitfield LR, Anderson JA. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fundam Appl Toxicol. 1996;32:285-292.
40. van der Spek E, Bloem AC, van de Donk NW, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica. 2006;91:542-545.
41. Yang Y-G, Dey B, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998;102:2126-2135.
42. Murphy W, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998;102:1742-1748.
43. Marks R, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF. Farnesyltransferase inhibitors inhibit T cell cytokine production at the post-transcriptional level. Blood. 2007;110:1982-1988.
44. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol. 2002;169:7111-7118.
45. Goldstein J, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35-46.
46. Carter L, Dutton RW. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J Immunol. 1995;155:1028-1031.